| Background: The apolipoprotein A5 (ApoA5) was the newestapolipoprotein discovered in 2001. It has been identified that thegenotype of ApoA5 was closely associated with the levels of triglyceride(TG) in human, and the rare allele carriers presented higher TG levelsthan the noncarriers. Some other reports revealed that the genovariationof ApoA5 may result in decreasing plasma levels of high densitylipoprotein cholesterol (HDL-C). It is known to all that high TG and lowHDL-C levels are indepentant risk factors for coronary heart disease(CHD), and such abnormal lipid profiles always accompany with insulinresistance. So the association of ApoA5 with CHD and diabetes attractedresearchers' attention for the past few years. Besides that, a hormonesecreted from adipocyte called adiponectin also participates in themetabolism of glucose and lipids, and the levels of adiponectin werefound to be lowered in patients with CHD and diabetes. However, therelationship between the concentrations of ApoA5 and the levels ofinsulin and adiponectin are unclear, and there are very few reportsreferring to this.Objectives: To explore the changes of serum concentrations ofApoA5, and the relationship with levels of adiponectin and insulin inpatients with CHD. Furthermore, to evaluate the correlation of the serum ApoA5 levels with the CHD susceptibility.Methods and subjects: We selected 115 subjects, consisted of 61patients with CHD (including 41 males and 20 females, the average agewas 60.73±9.83 years) and 54 healthy controls (including 35 males and19 females, the average age was 58.32±6.56 years). Each wereexamined the blood lipids, the serum concentrations of ApoA5,adiponectin and insulin levels. In the end, the homeostasis modelassessment of insulin resistance (HOMA-IR) index were calculated.Results:1. The concentrations of ApoA5 and adiponectin in patients withCHD were significantly lower than in the healthy controls (230.06±115.8ng/ml and 3.03±1.85ug/ml vs. 324.43±151.79ng/ml and 4.12±2.48ug/ml, respectively, all p＜0.05); whereas fasting seruminsulin(FINS) levels and HOMA-IR index were significantly higher thanthe healthy controls (9.85±5.94mu/l and 2.71±1.58 vs. 7.85±3.04mu/land 1.69±0.71, all p＜0.05).2. Linear correlation analysis indicated that the concentrations ofApo A5 were inversely correlated with ages, TG levels, FINS levels andHOMA-IR index (r=-0.294, -0.268, -0.222 and -0.254, respectively:all P＜0.05); but positively correlated with HDL-C levels (r=0.38,P＜0.01). However, no relationship was found between ApoA5 andadiponectin. 3. Partial correlation analysis adjusted for ages showed that theconcentrations of ApoA5 still inversely correlated with TG, FINS andHOMA-IR index (r=-0.23, -0.22 and -0.24 respectively, all P＜0.05); andpositively correlated with HDL-C (r=0.33, P＜0.05).4. Univariate logistic regression showed that adiponectin, diabetesand HDL-C were the major candidates for CHD. However, theconcentrations of ApoA5 did not show statistically correlation with CHD(OR=0.996, 95%CI=0.990-1.003, P=0.277).Conclusions:1. The patients with CHD have decreased serum levels of ApoA5and adiponectin, but increased levels of insulin.2. The concentrations of ApoA5 were negatively correlated withTG and FINS levels, but positively correlated with HDL-C levels.3. ApoA5 can influence blood lipids, which may partly attribute tothe effects of insulin resistance.4. The concentrations of ApoA5 may not be the major risk factorsfor CHD. |
PDF Full Text Request